Latest news and press releases about Zai Lab Limited (ZLAB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders.
Price
| Price | $24.67 |
| Market Cap | $2.8B |
| Exchange | NASDAQ |
| Country | CN |
Valuation Ratios
| Price / Book | 2.76 |
| EV / EBITDA | -9.33 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -24.53% |
| Return on Invested Capital | -22.74% |
| Return on Assets | -14.97% |
| Gross Margin | 58.47% |
| Operating Margin | -48.59% |
| Net Margin | -38.15% |
Related companies: AAPG · APGE · CDTX · CNTA · IDYA · IRON · LEGN
Explore sector: Healthcare · Biotechnology
More sections of ZLAB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks